

VIVALYTIC VIRAL RESPIRATORY  
TRACT INFECTION ARRAY (VRI)  
Detecting SARS-CoV-2 (COVID-19)

The Vivalytic Viral Respiratory Tract Infection (VRI) Array can identify SARS-CoV-2 (COVID-19) and differentiate it from nine other respiratory infections with similar symptoms, including influenza and all known coronaviruses.

The test only requires a single nasal swab from the patient and an easy four step process to be carried out by the user.

Sample Type: Nasopharyngeal Swab  
Sample Volume: 300µl Clinical Sample  
Result Time: 2.5 Hours

VIRUSES
SARS-CoV-2 (COVID-19)
Sarbecovirus (SARS, SARS like, SARS-CoV-2)
Coronavirus 229E/NL63
Coronavirus OC43/HKU1
Middle East Respiratory Syndrome Coronavirus (MERS-CoV)
Adenovirus A/B/C/D/E
Enterovirus A/B/C
Influenza A
Influenza B
Rhinovirus A/B



## Vivalytic

### Cartridge Based Testing Platform

The new VRI test will be conducted on Vivalytic, a point of care platform brought to the market by Randox Laboratories and Bosch. The Vivalytic system is a fully-automated, cartridge-based platform capable of both Hi-Plex and Lo-Plex testing. The cartridges are fully-sealed which minimises the risk of contamination, require room temperature storage (space-saving), contain all the reagents on-board the cartridge and utilises end point PCR.

#### Vivalytic Key Features:

- Cartridge based platform
- Closed system
- Fully automated
- Suitable for both non-laboratory & laboratory settings
- Small footprint device

## Vivalytic Workflow

### 4 Easy Steps for Optimised Workflow

